Pfizer's Comirnaty vaccine is taking important steps in Mexico, as it has obtained initial approval from a committee of experts. This vaccine has been updated to combat the XBB.1.5 omicron variant, making it even more effective against COVID-19.
The Federal Commission for the Protection against Sanitary Risk (Cofepris) has given the green light to Pfizer's Comirnaty vaccine, which means it could be closer to reaching the Mexican market. The vaccine is designed for people six months and older and has been developed to combat new variants of the virus.
In the evaluation meeting, experts discussed the technical and scientific information provided by Pfizer.
The good news is that the vaccine appears to generate a solid immune response. However, as with any medication, concerns have been raised about safety, such as myocarditis and pericarditis. Despite these potential risks, the benefits of the vaccine are considered to outweigh the risks for all ages and groups for which it is authorized.
Cofepris has also committed to continuing to monitor the safety of the vaccine and to conduct ongoing evaluations. Although the deliberations are not public, this time total transparency in the process has been promised, which is good news for the community.
With information from: El Economista.
Receive all industry news in our weekly Newsletter Scientific Dialectics.